Global Fecal Microbiota Transplantation Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Fecal Microbiota Transplantation Market Insights, Forecast to 2034
Fecal microbiota transplantation refers to the practice of transplanting stool from a healthy donor into the gastrointestinal tract of the patient. This procedure restores the balance of bacteria in the digestive tract by replenishing the population of ‘good’ bacteria that is either suppressed by the overpopulation of ‘bad’ bacteria or has been killed. Prepared fecal microbiota transplantation is a thoroughly screened process. It is carried out in the lower gastrointestinal tract through colonoscopy or enema and in the upper gastrointestinal tract through the nasoduodenal or nasogastric tube. Currently, fecal microbiota transplantation is being studied for the treatment of Clostridium difficile infection but can be used for the treatment of gut dysbiosis after heavy treatment such as chemotherapy. Patietns with recurrent clostridium infections treated with fecal microbiota transplantation have shown high rates of success. A study has found that 90% recurrent C. difficile cases treated with fecal microbiota transplantation achieve clinical resolution. Thus, this has elevated fecal microbiota transplantation as an emerging treatment for a wide range of disorders, including fibromyalgia, Parkinson’s disease, myoclonus dystopia, chronic fatigue syndrome, multiple sclerosis, insulin resistance, obesity, metabolic syndrome, and autism.
Market Analysis and InsightsGlobal Fecal Microbiota Transplantation Market
Global Fecal Microbiota Transplantation market is expected to reach to US$ 282 million in 2024, with a positive growth of %, compared with US$ 268 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Fecal Microbiota Transplantation industry is evaluated to reach US$ 386.6 million in 2029. The CAGR will be 5.4% during 2024 to 2029.
According to the Global Use of Medicines 2024 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Report Covers
This report presents an overview of global Fecal Microbiota Transplantation market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Fecal Microbiota Transplantation market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Rebiotix
Finch Therapeutics
Seres Therapeutics
Crestovo
Segment by Type
Phase-I
Phase-2
Phase-3
Phase-4
Clostridium Difficile Infections
Parkinson Disease
Obesity
Diabetes Mellitus
Autism
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Fecal Microbiota Transplantation introduction, etc. Fecal Microbiota Transplantation Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Fecal Microbiota Transplantation
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Fecal Microbiota Transplantation Market
Global Fecal Microbiota Transplantation market is expected to reach to US$ 282 million in 2024, with a positive growth of %, compared with US$ 268 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Fecal Microbiota Transplantation industry is evaluated to reach US$ 386.6 million in 2029. The CAGR will be 5.4% during 2024 to 2029.
According to the Global Use of Medicines 2024 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Report Covers
This report presents an overview of global Fecal Microbiota Transplantation market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Fecal Microbiota Transplantation market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Rebiotix
Finch Therapeutics
Seres Therapeutics
Crestovo
Segment by Type
Phase-I
Phase-2
Phase-3
Phase-4
Segment by Application
Clostridium Difficile Infections
Parkinson Disease
Obesity
Diabetes Mellitus
Autism
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Fecal Microbiota Transplantation introduction, etc. Fecal Microbiota Transplantation Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Fecal Microbiota Transplantation
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports